Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials

    Clinical Journal of the American Society of Nephrology Date published:

  • Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

    Arthritis & Rheumatology Date published:

  • Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:

  • WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

    Kidney International Reports Date published:

  • The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

    Kidney International Reports Date published:

  • WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS

    Kidney International Reports Date published:

  • WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

    Kidney International Reports Date published:

  • WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

    Kidney International Reports Date published:

  • WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

    Kidney International Reports Date published:

  • Daprodustat and Heart Failure in CKD

    Journal of the American Society of Nephrology Date published:

  • Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial

    Journal of the American Society of Nephrology Date published:

  • Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

    The Lancet Regional Health - Western Pacific Date published:

  • VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

    Journal of the American Society of Nephrology Date published:

  • Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE trials

    Diabetes Care Date published:

  • Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

    Journal of the American Heart Association Date published:

  • The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Date published: